The longer a healthcare worker diverts drugs, the more patients can be put at risk
September 08, 2020
Invistics, the leading provider of advanced inventory visibility and analytics software, has released the latest major update of Invistics’ Flowlytics software, including new features for healthcare systems drug diversion solutions. These capabilities allow organizations to integrate data from multiple IT systems across departments and facilities, including inpatient healthcare facilities, as well as ambulatory and outpatient operations such as retail pharmacies, ambulatory surgical centers, and infusion centers.
Healthcare organizations benefit from the ability to uncover potential diversion across departments and facilities and surface potential thefts quickly — in days, or even hours –reducing the time it takes to discover potential drug diversion. Flowlytics, unique among existing drug diversion solutions, can also help detect more incidents overall by tracking medications from the wholesaler purchase all the way through the organization until they are administered to patients or safely destroyed.
Drug diversion expert Russ Nix, founder of Aegis RX, says the speed of detection is critical in healthcare facilities to protect patients from risk. “The time between when a drug diversion incident occurs and when it is adjudicated is extremely valuable. The longer a healthcare worker diverts drugs, the more patients can be put at risk,” said Nix. “Now, Invistics has added those same drug diversion detection capabilities to multiple departments and facilities, creating a network of data that can expose more potential diversion incidents with speed and accuracy.”
The new Flowlytics features provide the following additional benefits:
More efficient investigation: Permitted users can now review Personally Identifiable Information (PII) within the software, with full Health Insurance Portability and Accountability Act (HIPAA) compliance.
- Improved usability: All modules are now logically aligned with drug diversion prevention workflow best practices: detection, investigation, adjudication and reporting. This alignment of reports with workflow steps will make it easier for staff to investigate diversion, with a full audit trail of investigation notes and information.
- Improved data security: Health systems with multiple locations can use Data Access Levels to allow some drug diversion investigators to see all data, while limiting data visibility for others to specific locations or departments.
“Invistics is in a unique place to solve drug diversion issues for healthcare organizations, with a long history of providing solutions that optimize inventory and make it continually visible across multiple departments, businesses and IT systems in complex, global supply chains,” said Invistics founder and Chief Executive Officer, Tom Knight. “These leaky supply chains also exist in healthcare organizations, where inventory includes controlled substances and expensive oncology drugs and biologics. We are applying advanced analytics and machine learning to help detect drug diversion quickly and efficiently, while significantly reducing the hassles of regulatory reporting—issues that every healthcare organization needs to address.”
Invistics is the leading provider of cloud-based drug diversion solutions for healthcare inventory visibility, providing advanced analytics and actionable insights for hospitals and health systems who want to detect and prevent drug diversion. Invistics’ solution, called Flowlytics®, tracks the movement of drugs across the complex supply chain – from the time they are shipped from the wholesaler to a healthcare facility, then each time drugs are moved throughout the hospital and administered to patients. Atlanta-based Invistics Corporation also provides inventory visibility for manufacturers, distributors, re-packagers and controlled substance registrants, helping to reduce inventory costs and compliance risks within a single facility or across the extended enterprise. To learn more, visit https://www.invistics.com.
Share article on social media or email: